Concepedia
Statistics
Publications
1
Citations
143
H-Index
Active since
2007
Hm Kantaijian is an author specializing in bcr-abl1 fusion gene, cytogenetics, and bcr-abl inhibitors.
Publications per year
2007–2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hm Kantaijian · Blood · 2007 · 143 citations
Medicine, Oncology, Pharmacology +9
1–1 of 1